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Objective: Infrainguinal autogenous vein grafts are especially prone to narrowing and failure, and both inflammatory and
thrombotic pathways are implicated. Platelets and monocytes are the key thrombo-inflammatory cells that arrive first at
sites of vascular injury. These cells have potent interactions that recruit and activate one another, propagating thrombotic
and inflammatory responses within the vessel wall. We therefore hypothesized that elevated levels of platelet-monocyte
aggregates (PMA) might be associated with stenosis, and could possibly discriminate between patients with or without
vein graft stenosis.
Methods:Thirty-six vascular surgery patients were studied, in a stable quiescent period after infrainguinal autogenous vein
graft bypasses for occlusive disease. Eighteen patients had hemodynamically significant graft stenoses confirmed by
imaging, and 18 were free from stenosis. The level of PMA in whole blood was quantified after blood draw using
two-color flow cytometry. Three measurements were made per sample: the basal, in-vivo level of aggregates (baseline
PMA); the predisposition to spontaneously generate PMA (spontaneous PMA); and PMA generation by the addition of
exogenous thrombin receptor-activating peptide (stimulated PMA). The baseline, in-vivo level of PMA was estimated by
immediate flow analysis. The predisposition to spontaneously generate PMA was measured after in vitro incubation.
Responsiveness to thrombin stimulation of the blood was quantified by the in vitro dose response to an exogenous
thrombin receptor-activating peptide (sfllrn).
Results: Baseline PMA levels were similar in patients with vein graft stenosis vs nonstenosis (14.8% 3.2 vs 10.1% 1.5,
respectively, mean  SEM). However, patients with stenosis showed higher spontaneous PMA levels (58.5%  4.5 vs
28.3%  4.3; P < .001) and higher stimulated PMA levels (P < .001; analysis of variance). Covariables of smoking,
diabetes, statin, or antithrombotic therapy could not account for these differences.
Conclusions: Platelet-monocyte reactivity may play a role in the development of vein graft stenoses. Those with/without
stenosis differed primarily in their threshold, or predisposition to form aggregates (spontaneous PMA), while their basal
circulating levels of PMA (baseline PMA) were similar. These measurements may unmask pathologic differences in
thrombo-inflammatory responsiveness that are not apparent in basal measurements. Understanding the causes and
mechanisms leading to abnormal platelet-monocyte responses may improve approaches to predicting or preventing vein
graft stenosis. ( J Vasc Surg 2011;54:1124-30.)
Clinical Relevance: Infrainguinal autogenous vein grafts are especially prone to narrowing and failure with both
inflammatory and thrombotic pathways implicated. Platelets and monocytes are key thrombo-inflammatory cells that
arrive first at sites of vascular injury. These cells have potent interactions that recruit and activate one another,
propagating thrombotic and inflammatory responses within the vessel wall. Excessive platelet-monocyte interactions are
associated with myocardial infarction, unstable coronary syndrome, and cerebral vascular accidents. This article bridges
clinical and basic science. It has a potentially large clinical impact in that it could lead to development of methods that
identify patients who have increased risk of graft failure and provide clues that help with the design of drugs that limit
thrombo-inflammatory processes that lead to graft failure.
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vVein graft stenosis and pathologic vascular wall thick-
ening are critical problems in vascular surgery, affecting
15% to 30% of infrainguinal grafts within the first year after
surgery.1-5 Graft stenosis is a leading cause of reoperation,
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1124raft failure, and limb loss,6,7 and yet the contributory
actors are poorly understood. Most authorities consider
ein graft stenosis, fibrosis, and anastomotic intimal hyper-
lastic lesions as a spectrum of related pathologic process-
s.8-10 Although there is significant variability among dif-
erent patients’ clinical responses to vascular injury, little is
nown about what accounts for these differences, especially
atients with peripheral arterial disease (PAD).
Research suggests that the processes of inflammation
nd thrombosis, with their extensive biological crosstalk,
nderlie the pathologic response to vascular injury. Blood
latelets and monocytes are among the first inflammatory
ell types to arrive at sites of vascular injury.11,12 Through
ell-cell adhesion and costimulation, they initiate both
hrombotic and inflammatory responses, propagating acti-
ation to the endothelium and vascular smooth muscle
ells. A broad range of basic and clinical studies have shown
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Volume 54, Number 4 Moreno et al 1125a close association between platelet and monocyte activity,
derangements of vascular healing, and cardiovascular clin-
ical outcomes.13,14 In particular, the measurement of cir-
culating platelet-monocyte aggregates (PMA) in the blood
has become a powerful new tool to assess this systemic
thrombotic and inflammatory state.15,16 Elevated PMA
have been closely associated with myocardial infarction,
unstable coronary syndrome, percutaneous coronary inter-
vention, restenosis, and smoking.15-24 Recently, Burdess et
al have shown that PMA are elevated in subjects with PAD
and critical limb ischemia.25
We hypothesized that differences in platelet-monocyte
activation, as measured by the formation of PMA, might
account in part for the differences in biological healing of
autogenous vein grafts. We also wished to learn exactly
what kinds of measurements of PMA formation might
better discriminate between patients with different throm-
botic/inflammatory phenotypes and clinical outcomes.
Therefore, we conducted this pilot study to elucidate the
feasibility and utility of measuring PMA formation in pa-
tients with peripheral arterial disease with vein grafts and to
determine if assessments of platelet monocyte interaction
might be associated with vein graft stenosis.
METHODS
Measurement of PMA in whole blood. For all as-
says, blood was collected into vacutainer tubes containing
3.2% sodium citrate (BD Medical Systems, Franklin Lakes,
NJ) by clean, flawless venipuncture using a modification of
the two-syringe technique and a void volume of at least 3
mL. From the single venous blood sample, one aliquot was
immediately treated with EDTA (5mM). This halts further
aggregation ex vivo immediately after it is drawn. We call
this the “baseline PMA” level because it is before we subject
the blood to various conditions of incubation. A second
aliquot was incubated with phosphate buffered saline
(PBS). During this incubation, platelets and monocytes
continue to aggregate together spontaneously. We call this
the “spontaneous PMA” level. A final series of aliquots was
exposed to increasing concentrations of thrombin receptor-
activating peptide (TRAP; peptide SFLLRN, 1-5 Molar).
This stimulates the platelets and monocytes to aggregate
and reflects thrombin sensitivity. We call the TRAP-stimu-
lated incubation the “stimulated PMA” level.
Samples were incubated 15 minutes with mouse anti-
human CD-41 conjugated PE antibody (platelet labeled),
and mouse anti-human CD 14 conjugated FITC antibody
(monocyte labeled): both antibodies were obtained from
Dako Cytomation (Carpinteria, Calif). Controls used to
determine background fluorescence were nonspecific anti-
bodies matched for isotype, fluorophore, concentration,
and F:P ratio (BD BioSciences). The cells were then fixed
with formalin (1.3  Hanks/0.5% formaldehyde, final
concentration) for 10 minutes and then lyzed with 6 vol-
umes of water. All incubation steps were performed at
room temperature in the dark. Samples were kept at 4°C
until analyzed. cFlow cytometric quantification of platelet-monocyte het-
rotypic aggregates was performed on a BD Biosciences (San
ose, Calif) FACSCalibur, using the standard methods of
ichelson et al.16,26 Samples were run on a low-flow setting,
ollecting light-scatter data in linear mode, with the threshold
et on forward light scatter. A minimum of 1,000 CD14-
ositive monocytes are quantified. Within the dot plot of
ide scatter versus log FITC-CD14, the monocyte region
f interest is chosen, from which histograms of cell count
ersus log (phycoerythrin-CD41 fluorescence) are devel-
ped. The positive marker is set just above the isotype-
egative histogram to include 1% of the total fluores-
ence. The parameter of interest is then measured as the
ercentage of monocytes positive for phycoerythrin stain-
ng platelets (% PMA).
As reported by Michelson and others, we found in
ontrol experiments that after cell fixation, sample results
re stable and reproducible for at least 24 hours of refrig-
ration.27 We also compared the natural agonist, human
lpha-thrombin, to the TRAP, using established meth-
ds.27 TRAP was used as the thrombin agonist because
omparable results were obtained with both agonists. Dur-
ng the development of our methods, we also measured the
ormation of platelet-polymorphonuclear cell aggregates
nd found that those levels closely paralleled those of PMA.
e chose to focus on the monocyte because of its unique
nflammatory potential and its proven role in impaired
ascular healing.
Patient selection criteria. The population under
tudy included those patients with established infrainguinal
ein grafts undergoing routine postoperative follow-up at
he Veterans Administration Puget Sound Health Care
ystem and the University of Washington Medical Center.
his included patients undergoing elective infrainguinal
eripheral bypass grafting (redo and primary bypasses) with
utogenous vein graft. Indications for surgery included
able I. Frequency and distribution of clinical
haracteristics in the subject population
linical
haracteristic
Stenosis
(n  18)
No stenosis
(n  18)
All patients
(n  36)
ean age (range) 65.5 (41-84) 68.7 (55-90) 67.1 (41-90)
emale gender 6 (33%) 3 (17%) 9 (25%)
iabetic 7 (39%) 6 (33%) 13 (36%)
tatin Rx 13 (72%) 15 (83%) 28 (78%)
arfarin Rx 9 (50%) 3 (17%) 12 (33%)
spirin Rx 9 (50%) 16 (89%) 25 (69%)
lopidogrel Rx 3 (17%) 1 (6%) 4 (11%)
ctive smoker 9 (50%) 10 (56%) 19 (53%)
x, Therapy.
ive patients were taking both an antiplatelet drug and warfarin.
ll of these clinical characteristics were evenly distributed (2 or Fisher’s
xact test) between both groups, except aspirin Rx (P  .03).
multivariate analysis of PBS values, looking at covariables of aspirin
herapy, diabetes, and smoking were not significant, and had no interactions
ith the factor of stenosis.
ercentages are rounded.laudication, rest pain, and tissue loss without active infec-
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October 20111126 Moreno et altion. Those with indication for tissue loss had healed
wounds at the time of blood draw. The subjects were
recruited at their follow-up duplex visits. All vein graft
patients undergo regular duplex ultrasound surveillance at
3, 6, 12, 18 months, and then yearly. Because this was a
pilot study, eligible subjects were recruited as they arose,
over a 2-year period, and those without stenosis were not
matched for comorbid conditions.
Inclusion criteria were: (1) A patent, autogenous vein
infrainguinal bypass graft performed for atherosclerotic
occlusive vascular disease. Patency was determined postop-
eratively in the operating room by either ultrasound duplex
or angiography. (2) Either the presence or absence of a vein
graft stenosis. All subjects had single-segment autogenous
vein conduits. Stenotic patients were included if they had a
hemodynamically significant stenosis (greater than 75% or
velocity ratio greater than 3.5)28 as detected by duplex
ultrasound and confirmed with complementary vascular
imaging when equivocal. Subjects with complete occlusion
were excluded from the study.
Nonstenotic patients were included if they had consis-
tently normal duplex graft surveillance studies throughout
their follow-up. Exclusion criteria eliminated patients with
known hypercoagulable states or intercurrent thrombotic
or inflammatory conditions that might affect a patient’s
usual, chronic state of platelet and monocyte reactivity,
namely recent surgery or arteriography, active infection, or
other transient medical condition that might influence the
measurements (eg, myocardial infarction, stroke). Patients
with immediate occlusion or occlusion before 6 months
Fig 1. Platelet-monocyte aggregate (PMA) formation i
ous, and the stimulated formation of PMA by throm
described in the Methods section. Vein graft patients
stimulated aggregate formation than normal subjects
determined by t test (spontaneous generation, P  .04)postoperatively were excluded. dNormal healthy individuals who were free of platelet-
ctive or anti-inflammatory drugs were also recruited for
tudy as normal controls. These normal healthy subjects
ere used as our control group to the subjects with periph-
ral vascular disease. All subjects were recruited and studied
n an outpatient setting, after informed consent. The study
nd its protocols were approved by the Institutional Review
oard of the University of Washington and the Veterans
dministration Puget Sound Health Care System, and all
ubjects gave informed consent.
Data analysis. The significance of between-group dif-
erences in continuous variables (eg, PMA levels) was de-
ermined by t test or analysis of variance, using Systat (San
ose, Calif) software. The proportions of dichotomous
ariables were tested by 2 analysis or Fisher’s exact test.
eans with standard error of the mean are presented, and
wo-tailed P values .05 were considered significant.
ESULTS
atient characteristics
A total of 36 patients were studied. All of the 18 with
tenosis had either a hemodynamically critical single graft
tenosis awaiting surgical correction or had a history of
revious surgically corrected graft stenosis plus a new,
ncorrected stenosis. Eighteen patients were studied who
ever had any stenosis of their vein grafts, which were
idely patent throughout their surveillance follow-up. All
atients were recruited at least 6 months from their primary
urgery, and at least 3 months from any surgical proce-
mal subjects and vein graft patients. Baseline, spontane-
eceptor-activating peptide (TRAP) were measured as
36) had significantly higher spontaneous and TRAP-
34). Means and SEM are shown, with significance
nalysis of variance (TRAP response, P  .001).n nor
bin r
(n 
(n ures. Eighteen of the 36 patients studied underwent du-
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The clinical characteristics of the 36 patients are listed in
Table I. All patients were of the Caucasian race. Thirty-four
healthy volunteer subjects were also studied, of whom 10
were female, and all were Caucasian. These individuals were
studied as a healthy control group to establish normal
benchmarks and were not intended to be a matched clinical
cohort for the vein graft patients. Repeated measurements
taken from the same subject on different weeks showed
consistent, reproducible results. The coefficient of repeat-
ability (Bland Altman) for this was 10%.
PMA in healthy volunteer subjects compared with
vein graft
Patients. Three basic measures of platelet-monocyte
reactivity were performed: (1) Baseline PMA obtained by
the immediate suppression of further aggregate formation
by incubation with 5mMEDTA; (2) Spontaneous PMA by
incubation with PBS; and (3) Stimulated PMA by incubat-
ing with increasing concentrations of TRAP. Fig 1 com-
pares the healthy, normal subjects to the group of all vein
graft patients. Baseline values of PMAwere not significantly
different between the PAD patients and healthy normals
(12.5% 1.8 vs 10.9% 1.2, respectively). As anticipated,
the patients with PAD had significantly higher spontaneous
(43.4%  4.3 vs 31.8%  4.1; P  .04) and stimulated
formation of PMA compared with the healthy normals
(P  .001, two-way analysis of variance).
Association between PMA and graft stenosis. Com-
paring the patients with stenosis with those without steno-
Fig 2. Platelet-monocyte aggregate formation (PMA) in
the stimulated formation of PMA by thrombin receptor-
Methods section. Patients with vein graft stenosis had
stimulated aggregate formation (P  .001) Means an
(spontaneous generation) and analysis of variance (TRAsis (Fig 2), the baseline PMA values were also not signifi- fantly different (14.8% 3.2 vs 10.1%1.5, respectively).
owever, the spontaneous generation of PMA in the ste-
osis patients was significantly higher than in those without
tenosis (58.5% 4.5 vs 28.3% 4.3; P .001). Likewise,
he differences in their responses to the thrombin agonist
stimulated) were highly significant (P  .001, two-way
nalysis of variance). Fig 2 illustrates the composite data
rom these three measures.
These results indicate that patients with clinically severe
ein graft stenosis had significantly higher spontaneous and
timulated formation of PMA. We found that measure-
ents of the spontaneous generation of PMA discrimi-
ated better than the baseline levels did. It distinguished
ormals from vein graft patients, and those with stenosis
nts with or without stenosis. Baseline, spontaneous, and
ting peptide (TRAP) were measured as described in the
ificantly higher spontaneous (P  .001) and TRAP-
M are shown, with significance determined by t test
onse).
able II. Values of spontaneous platelet-monocyte
ggregates in patients with different clinical characteristics
linical Factor Present (n) Absent (n) P value
raft stenosis 58.5%  5.718 28.3%  4.318 .001
iabetes 58.7%  8.313 42.8%  5.123 NS
ntiplatelet Rx 37.4%  5.624 NS vs warfarin
arfarin Rx 63.9%  9.17
moking 44.9%  6.319 41.5%  5.917 NS
S, Not significant; Rx, therapy.
he averagemeasurements of spontaneous platelet-monocyte aggregates (
EM) are shown for patients with or without the listed clinical factors.
ntiplatelet Rx includes all patients exclusively taking aspirin and/or clopi-
ogrel, but not warfarin.
arfarin Rx includes only those on warfarin.patie
activa
sign
d SErom those without stenosis. Likewise, the level of throm-
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effective discriminator than baseline values.
Influence of other clinical factors on PMA and graft
stenosis
Although the clinical, systemic risk factors for vein graft
stenosis are not known, potentially confounding factors
could include conditions such as diabetes and smoking,
which have been associated with increased PMA. Table I
summarizes the clinical factors of the 36 patients. The
clinical factors listed in Table I were evenly distributed
between the two groups, except for aspirin therapy (P 
.03). Three of the patients included were on both aspirin
and warfarin therapy, and all patients that were not on
aspirin in both groups were on either warfarin, clopidogrel,
or both.
The average spontaneous PMA values were not signif-
icantly different among those patients with/without diabe-
tes, an active smoking habit, and those on antiplatelet
versus warfarin therapy (Table II). A multivariate analysis
on PBS values, looking at covariables such as aspirin ther-
apy, diabetes, and smoking were not significant and had no
interactions with the factor of stenosis. Statin therapy bore
no relation to PMA values (data not shown), although only
eight patients were not taking a statin. This does not rule
out the possibility that any of them could be a confounding
factor.
Many patients were receiving diverse combinations of
antiplatelet and anticoagulant drugs, so the numbers were
too small to conduct a multivariate analysis of the effects of
all the different combinations of antithrombotic drugs.
However, we did compare the PMA values from those
Fig 3. Platelet-monocyte aggregate formation (PMA)
Baseline, spontaneous, and the stimulated formation of
Measured as described in the Methods section. Only pa
analysis: ASA (n 21), clopidogrel (n 3), warfarin (n
between the groups was the spontaneous generation v
(P  .02).patients who were exclusively treated with a single anti- thrombotic drug (Fig 3). The only significant differences in
aseline, spontaneous, and stimulated PMA levels were
etween the spontaneous PMA levels between the aspirin-
nly group and the warfarin-only group (P  .02).
ISCUSSION
There were several purposes to this pilot study. First,
e wished to test the association between PMA and the
resence of pathologic vein graft stenosis. Second, we
ished to determine which types of measurements of
latelet-monocyte interactions might best discriminate
mong patients with different patterns of vascular healing
ie, stenosis). Burdess et al measured PMA in a variety of
atients with PAD.25 Using their slightly different method
f blood collection and processing, they reported PMA
evels of 30% to 40%, which is quite close to the value of
40% spontaneous PMA that we measured in our overall
roup of patients with PAD.
This was not a prospective study in which medications
r other clinical factors might be controlled or randomized,
nd as such, it has several limitations. Although the consis-
ency and accuracy of our techniques for measuring PMA
ere sufficient to discriminate between those with/without
tenosis, we were not able to quantitatively assess the
ndividual contributions of other clinical factors, perhaps
ecause of the limited number of subjects.
Platelets and monocytes are at the root of the primor-
ial cellular responses that lead to both thrombosis and
nflammation at sites of vascular injury.18,29-32 It has been
ell-established that patients with PAD suffer from in-
reased platelet reactivity and aggregability.33 Michelson
nd others have persuasively argued that PMA are one of
in graft patients according to antithrombotic therapy.
by thrombin receptor-activating peptide (TRAP) were
taking a single antithrombotic drug were included for
he only statistically significant difference in comparison
between the warfarin-only and the aspirin-only groupin ve
PMA
tients
7). T
alueshe most sensitive measures of platelet activation.16 How-
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intimately involved in the pathologic vascular inflammation
that is found in atherosclerosis as well as restenosis.34
Cross-talk between activated platelets and monocytes
operates through at least four major pathways: the P-
selectin/PSGL-1 receptor/counter-receptor system found
on platelets and monocytes, respectively30; the CD40/
CD40L axis35,36; monocyte integrin Mac-1 (M	2,
cd11b/cd18) binding to the platelet vonWillebrand recep-
tor, GpIb37-39; and finally, platelet integrin IIb	3 and the
monocyte integrin M	2 can share the same ligand, fibrin-
ogen. It is reasonable to speculate that platelets and mono-
cytes, working through their extensive costimulatory path-
ways, may contribute significantly to the deranged vascular
remodeling that causes vein graft stenosis.
A larger-scale, prospective clinical study will be needed
to resolve whether the observed increases in PMA forma-
tion are the cause of stenosis or the result of turbulence
caused by the stenosis. Anecdotally, we have not observed a
significant drop in PMA levels after the repair of stenoses in
several patients. To address this question of which comes
first, we are now measuring PMA before and after bypass
surgery and prospectively monitoring the development of
vein graft stenosis. A larger-scale study should also provide
sufficient data to help elucidate the fundamental mecha-
nisms underlying the elevated platelet and monocyte reac-
tivity in certain patients with PAD.
Other local factors such as graft diameter and quality,
velocity and turbulence of flow, compliance mismatch, and
technical factors are believed to contribute to premature
graft failure in some cases. Studies employing broader
definitions of “graft failure” have also demonstrated asso-
ciations with a patient’s inflammatory state.39,40 Stent re-
stenosis has also been correlated with inflammatorymarkers
in peripheral arterial stenting and in the coronary circula-
tion.22,41-44
Regarding the methodology for measuring PMA, we
found that provocative measurements of PMA could more
robustly differentiate between relatively small groups of
patients with/without stenosis. Looking to the future of
biomarkers to predict vein graft stenosis, we imagine that
stimulatory tests, which measure a patient’s biological ten-
dencies, may be more useful than baseline measurements.
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